Search results

What is the molecular weight/Mw of IFNG HUMAN, HIS ACTIVE Protein?
IFNG HUMAN, HIS ACTIVE Protein has a total Mw of 18.4kDa.

What is the source or expression system of IFNG HUMAN, HIS ACTIVE Protein?
Escherichia Coli.

What is the Purity of IFNG HUMAN, HIS ACTIVE Protein?
IFNG HUMAN, HIS ACTIVE Protein is >90% pure as determined by SDS-PAGE.

What is the Biological Activity of IFNG HUMAN, HIS ACTIVE Protein?
Measured in a cytotoxicity assay using WiDr cells. The ED50 for this effect is ≤ 5 ng/ml.

What is the amino acid sequence of IFNG HUMAN, HIS ACTIVE Protein?
MGSSHHHHHH SSGLVPRGSH MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFRG.

What applications can IFNG HUMAN, HIS ACTIVE Protein be used in?
IFNG HUMAN, HIS ACTIVE Protein can probably be used in western blot, ELISA and Lateral Flow.

What is the endotoxin level for IFNG HUMAN, HIS ACTIVE Protein?
The endotoxin level is minimal, IFNG HUMAN, HIS ACTIVE Protein was purified using conventional chromatography techniques.

CD4 protein, also known as Cluster of Differentiation 4, is a cell surface glycoprotein primarily expressed on helper T cells. It plays a crucial role in immune system regulation by mediating interactions between T cells and antigen-presenting cells (APCs). This research aims to explore the function, signaling pathways, and significance of CD4 protein in T cell biology and disease pathogenesis.

Function of CD4 Protein:

CD4 protein serves as a co-receptor for the T cell receptor (TCR) and interacts with major histocompatibility complex class II (MHC-II) molecules on APCs. This interaction enables CD4+ T cells to recognize and respond to antigenic peptides presented by MHC-II. CD4 protein enhances TCR signaling and facilitates the formation of immunological synapses between T cells and APCs, thereby promoting efficient T cell activation, proliferation, and differentiation.

Role of CD4 Protein in T Cell Differentiation:

CD4 protein is involved in determining the differentiation fate of CD4+ T cells. By interacting with specific cytokines secreted by APCs, CD4 protein directs the differentiation of naive T cells into distinct effector T cell subsets, including Th1, Th2, Th17, and regulatory T cells (Tregs). Each subset exhibits unique functions and cytokine profiles, contributing to immune responses, inflammation, and immune tolerance.

Signaling Pathways Activated by CD4 Protein:

Upon engagement with MHC-II, CD4 protein initiates signaling cascades that regulate T cell activation and differentiation. The cytoplasmic tail of CD4 contains conserved motifs, such as immunoreceptor tyrosine-based activation motifs (ITAMs) and proline-rich regions, which recruit and activate various signaling molecules, including protein kinases and adaptor proteins. These signaling events culminate in the activation of transcription factors, such as NF-κB and AP-1, which control gene expression required for T cell function.

Implications of CD4 Protein in Disease Pathogenesis:

Dysregulation of CD4 protein expression or function can lead to immune dysfunctions and contribute to the development of various diseases. CD4 protein is a primary receptor for human immunodeficiency virus (HIV) entry into CD4+ T cells, resulting in the destruction of these crucial immune cells and the progression of acquired immunodeficiency syndrome (AIDS). Moreover, altered CD4+ T cell responses and imbalances in T cell subsets have been associated with autoimmune diseases, allergic reactions, and chronic inflammatory conditions.

Conclusion:

The investigation of CD4 protein in T cell biology provides valuable insights into its role in immune system regulation and disease pathogenesis. Understanding the function and signaling pathways of CD4 protein enhances our knowledge of T cell activation, differentiation, and immune responses. Further research on CD4 protein may lead to the development of targeted therapies for immune-related disorders and provide novel strategies for immune modulation.

Hepatitis C virus (HCV) is a major global health concern, with approximately 71 million people infected worldwide. Chronic HCV infection can lead to liver cirrhosis, hepatocellular carcinoma, and other severe liver-related complications. The nonstructural proteins NS3, NS4, and NS5 of HCV play critical roles in viral replication, assembly, and immune evasion, making them attractive targets for antiviral interventions. This research aims to characterize the recombinant forms of HCV NS3, NS4, and NS5 proteins to gain insights into their functional properties and identify potential targets for the development of effective antiviral strategies.

The primary objective of this study is to express and purify recombinant HCV NS3, NS4, and NS5 proteins using suitable expression systems. Recombinant DNA techniques will be employed to generate expression vectors harboring the respective genes, followed by expression in bacterial, yeast, or mammalian cell-based systems. The recombinant proteins will be purified using affinity chromatography or other appropriate methods, enabling subsequent biochemical and biophysical characterization.

The second objective is to investigate the roles of NS3, NS4, and NS5 proteins in HCV replication and assembly. In vitro assays will be performed to assess the enzymatic activities of NS3 protease and NS5 RNA-dependent RNA polymerase (RdRp). The effects of potential inhibitors or small molecules on these enzymatic activities will be evaluated. Furthermore, the interactions between NS4 protein and cellular components involved in viral assembly will be explored using protein-protein interaction assays.

The third objective is to determine the three-dimensional structures of the recombinant NS3, NS4, and NS5 proteins using techniques such as X-ray crystallography or cryo-electron microscopy. Structural information will provide valuable insights into the functional domains and potential binding sites within these proteins. These findings will aid in the design of novel antiviral compounds targeting specific regions of NS3, NS4, and NS5, with the goal of disrupting viral replication and assembly.

By characterizing the recombinant forms of HCV NS3, NS4, and NS5 proteins, this research aims to enhance our understanding of the molecular mechanisms underlying HCV infection. The insights gained from this study may contribute to the development of novel antiviral strategies targeting HCV, ultimately leading to improved therapeutic options for individuals affected by this persistent and debilitating viral infection.

Human Immunodeficiency Virus type 1 (HIV1) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS), a devastating disease that affects millions of people worldwide. The HIV1 life cycle is a complex process involving several key viral enzymes, one of which is the integrase (IN). HIV1 integrase plays a crucial role in viral replication by catalyzing the integration of viral DNA into the host cell genome, an essential step for the establishment of a persistent infection.
The study of HIV1 integrase has been of great interest to researchers due to its significance as a therapeutic target. In recent years, advances in recombinant DNA technology have allowed for the production and purification of HIV1 integrase in recombinant form, enabling detailed structural and functional studies. This research aims to characterize the HIV1 integrase recombinant and gain insights into its mechanisms of action during viral integration.
The first objective of this study is to express and purify recombinant HIV1 integrase using various expression systems such as bacterial, yeast, or mammalian cell-based systems. Recombinant DNA techniques, including cloning and expression vector design, will be employed to generate the desired constructs for protein production. The recombinant integrase will be purified using affinity chromatography, followed by characterization using biochemical and biophysical techniques.
The second objective is to investigate the enzymatic activity of the purified HIV1 integrase recombinant. In vitro assays will be performed to determine its ability to catalyze the integration of viral DNA into target DNA sequences. Various substrates, including oligonucleotides and plasmids, will be used to assess the substrate specificity and kinetics of the integrase enzyme. Furthermore, the effects of potential inhibitors or small molecules on the enzymatic activity will be evaluated.
The third objective is to elucidate the three-dimensional structure of the HIV1 integrase recombinant using techniques such as X-ray crystallography or cryo-electron microscopy. This structural information will provide valuable insights into the mechanism of integrase function and aid in the rational design of novel inhibitors targeting integrase.
By characterizing the HIV1 integrase recombinant, this research aims to contribute to our understanding of the molecular mechanisms underlying viral integration. The findings from this study may provide crucial information for the development of novel therapeutic strategies targeting HIV1 integrase, potentially leading to the discovery of more effective antiretroviral drugs.

Recombinant HIV-1/2 Proteins play a crucial role in antiviral drug development. They serve as targets for drug screening, allowing researchers to identify compounds that inhibit key viral enzymes or interfere with viral entry. Moreover, these proteins are instrumental in studying drug resistance mechanisms, providing insights into how the virus adapts to selective pressures and guiding the development of more effective antiretroviral therapies.

Understanding Viral Dynamics and Host Interactions:
Studying Recombinant HIV-1/2 Proteins provides a lens into the dynamic interplay between the virus and host cells. These proteins help unravel the mechanisms of viral entry, integration into the host genome, and evasion of host immune surveillance. Insights gained from these studies are critical for devising strategies to disrupt viral replication and enhance the host's ability to control or eliminate the virus.

Challenges and Future Directions:
While the potential of Recombinant HIV-1/2 Proteins in HIV research is evident, challenges persist. Fine-tuning their applications, addressing issues of genetic diversity within HIV subtypes, and optimizing strategies for vaccine and drug development are critical considerations for translational success. Additionally, understanding the intricate host-virus interactions in different cellular contexts remains a dynamic area of investigation.

Recombinant HIV-1/2 Proteins stand as sentinel tools in the ongoing battle against HIV/AIDS, providing researchers with a nuanced understanding of viral dynamics and immune responses. Their structural insights, immunogenic properties, and applications in drug and vaccine development position them as central players in advancing our capabilities to combat HIV. As scientists continue to delve into the molecular intricacies of these recombinant proteins, they not only deepen our understanding of HIV pathogenesis but also pave the way for transformative advancements in HIV treatment and prevention, shaping the future of global health efforts against this formidable virus.

Procalcitonin is a hormone mostly produced by the C cells of the thyroid and specific endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into 3 specific fragments, an N terminal residue, katacalcin and calcitonin. Levels of unprocessed procalcitonin rise drastically after bacterial infection or shock.